SG11201806945SA - Cancer epigenetic profiling - Google Patents

Cancer epigenetic profiling

Info

Publication number
SG11201806945SA
SG11201806945SA SG11201806945SA SG11201806945SA SG11201806945SA SG 11201806945S A SG11201806945S A SG 11201806945SA SG 11201806945S A SG11201806945S A SG 11201806945SA SG 11201806945S A SG11201806945S A SG 11201806945SA SG 11201806945S A SG11201806945S A SG 11201806945SA
Authority
SG
Singapore
Prior art keywords
international
singapore
cancer
determining
genome
Prior art date
Application number
SG11201806945SA
Inventor
Patrick Tan
Wen Fong Ooi
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201806945SA publication Critical patent/SG11201806945SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110101111101011111111111101111101111011111 International Bureau .. .... ..Yejd ..... .....!;,,, (10) International Publication Number (43) International Publication Date WO 2017/142485 Al 24 August 2017 (24.08.2017) WI P0 I P CT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C12Q 1/68 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/SG2017/050073 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 16 February 2017 (16.02.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 10201601141X 16 February 2016 (16.02.2016) SG kind of regional protection available): ARIPO (BW, GH, 10201606828P 16 August 2016 (16.08.2016) SG GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Connexis North Tower, Singapore 138632 (SG). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CL CM, GA, GN, GQ, (72) Inventors: TAN, Patrick; c/o Genome Institute of Singa- pore, 60 Biopolis Street, Genome, #02-01, Singapore GW, KM, ML, MR, NE, SN, TD, TG). 138672 (SG). 001, Wen Fong; c/o Genome Institute of Declarations under Rule 4.17: _ Singapore, 60 Biopolis Street Genome, #02-01, Singapore — of inventorship (Rule 4.17(N)) 138672 (SG). Published: (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; — international 21(3)) = P.O. Box 1531, Robinson Road Post Office, Singapore with search report (Art. 903031 (SG). — with sequence listing part of description (Rule 5.2(a)) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, = = = = = = = = = = = 1-1 kin cc ii- ei - ii 1-1 (54) Title: CANCER EPIGENETIC PROFILING I N (57) : The present invention relates to a method for determining the presence or absence of at least one super-enhancer in a 1-1 C cancerous biological sample based on signal intensity of the histone modification H3K27ac. The present invention also relates to a N method for determining the prognosis of cancer in a subject, a method of determining the susceptibility of a subject to cancer or a O gastrointestinal disease and a method of predicting cancer cell survival or cancer cell viability by determining the presence or ab - ,..1: sence of at least one super-enhancer. The present invention also relates to inhibitors of CDX2 and/or HNF4a, such as metformin, and use thereof for modulating the activity of a super-enhancer.
SG11201806945SA 2016-02-16 2017-02-16 Cancer epigenetic profiling SG11201806945SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201601141X 2016-02-16
SG10201606828P 2016-08-16
PCT/SG2017/050073 WO2017142485A1 (en) 2016-02-16 2017-02-16 Cancer epigenetic profiling

Publications (1)

Publication Number Publication Date
SG11201806945SA true SG11201806945SA (en) 2018-09-27

Family

ID=59625365

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202007867PA SG10202007867PA (en) 2016-02-16 2017-02-16 Cancer epigenetic profiling
SG11201806945SA SG11201806945SA (en) 2016-02-16 2017-02-16 Cancer epigenetic profiling

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202007867PA SG10202007867PA (en) 2016-02-16 2017-02-16 Cancer epigenetic profiling

Country Status (7)

Country Link
US (1) US20210223249A1 (en)
EP (1) EP3417076B1 (en)
JP (2) JP7189020B2 (en)
KR (1) KR20180108820A (en)
CN (1) CN109072312A (en)
SG (2) SG10202007867PA (en)
WO (1) WO2017142485A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108085395A (en) * 2018-02-24 2018-05-29 韩林志 Primer sets, kit and the method for cervical carcinoma polygenes DNA methylation assay based on high-flux sequence
CN109735539B (en) * 2019-01-22 2022-06-03 南通大学 PDL1/PDL2 super-enhancer-based control method for regulating expression of PDL1 and PDL2
CN112111576A (en) * 2020-09-29 2020-12-22 杨帆 Method for screening nasopharyngeal carcinoma and application
CN114164210B (en) * 2021-08-19 2023-10-10 上海海洋大学 Long-chain non-coding RNA for regulating and controlling protooncogene MYB and application thereof
CN114525249A (en) * 2022-03-31 2022-05-24 广西大学 Muscle tissue extraction method for separating bovine muscle stem cells and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596192A (en) * 2009-08-25 2012-07-18 哈佛大学校长及研究员协会 Use of metformin in cancer treatment and prevention
WO2014066848A1 (en) 2012-10-25 2014-05-01 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
EP3090065B1 (en) * 2013-12-30 2019-12-11 Agency For Science, Technology And Research Methods for measuring biomarkers in gastrointestinal cancer
WO2017011710A2 (en) 2015-07-14 2017-01-19 Whitehead Institute For Biomedical Research Chromosome neighborhood structures and methods relating thereto

Also Published As

Publication number Publication date
JP7189020B2 (en) 2022-12-13
JP2019514344A (en) 2019-06-06
CN109072312A (en) 2018-12-21
EP3417076B1 (en) 2022-11-09
EP3417076A1 (en) 2018-12-26
SG10202007867PA (en) 2020-09-29
US20210223249A1 (en) 2021-07-22
EP3417076A4 (en) 2019-10-23
KR20180108820A (en) 2018-10-04
WO2017142485A1 (en) 2017-08-24
JP2023029945A (en) 2023-03-07

Similar Documents

Publication Publication Date Title
SG11201806945SA (en) Cancer epigenetic profiling
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201808494TA (en) Signal light detection
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201908564RA (en) Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions
SG11201808014SA (en) Compositions, devices, and methods for cell separation
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201901577SA (en) Method and system for fast tracking navigation of blockchains via data manipulation
SG11201807334SA (en) Methods, compositions, and devices for information storage
SG11201806946VA (en) Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma
SG11201806282XA (en) High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201805115PA (en) Detection and quantification of target nucleic acid sequence of a microorganism
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201804144UA (en) High-throughput imaging-based methods for predicting cell-type-specific toxicity of xenobiotics with diverse chemical structures
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201809996QA (en) Ribonucleic acid (rna) interactions
SG11201408163VA (en) Modified fibronectin fragments or variants and uses thereof
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201810914VA (en) Compositions and methods for diagnosing lung cancers using gene expression profiles